Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has recently revealed that it has entered into a securities purchase agreement for a private investment in public equity financing. The company expects to amass approximately $250 million in gross proceeds through this financing round, which will strengthen its financial position. The placement will involve the sale of approximately 2.3 million shares of Series A Convertible Preferred Stock, priced at $108.50 per share. This stock will be convertible into approximately 115.2 million shares of Lexicon’s common stock.
Facts:Lexicon Pharmaceuticals, Inc. has entered into a securities purchase agreement for a private investment in public equity financing.2. The financing round is expected to generate around $250 million in gross proceeds.3. The sale will involve approximately 2.3 million shares of Series A Convertible Preferred Stock.4. The price per share of the preferred stock is set at $108.50.5. The preferred stock can be converted into approximately 115.2 million shares of Lexicon’s common stock.6. The investment will be made by a select group of accredited investors.7. The cumulative net loss for Lexicon Pharmaceuticals Inc in the last 12 months, ending in the third quarter of 2023, was recorded at $-158 million.
Comments